The size of the MEA Neurotherapeutics Market is predicted to be growing at a sluggish CAGR between 2021 to 2026.
Neurological disorders are diseases of the central, peripheral, Autonomous nervous system. In other words, the brain, autonomic nervous system, spinal cord, peripheral nerves, cranial nerves, nerve roots, neuromuscular junction, and muscles. Some of these conditions like cerebral palsy, are present from birth, and Alzheimer’s disease, Parkinson’s disease affect mainly older people. So, Neurotherapeutics are used for the treatment of traumas causing diseases.
The factors that are driving the Middle East and Africa Neurotherapeutics Market are increasing geriatric population, increasing health care expenditure, increasing investment in R&D, a better understanding of the nature of neurologic diseases. Restrictions by regulatory bodies on various technologies and drugs, lack of proper reimbursement policy, Lack of awareness in developing countries are the factors that are hindering the growth of the market.
Based on Treatment, the market is segmented into Neurologic drugs and Neurologic devices. Neurologic drugs are further classified into oral administration, injections and others. Whereas neurologic devices are further categorized into Electroconvulsive Therapy (ECT), Vagus Nerve Stimulation (VNS), transcranial magnetic stimulation, Deep Brain Stimulator, and others. Based on disorders, the market is segmented into Central Nervous system (CNS) disorders, Peripheral Nervous system (PNS) disorders, Autonomous Nervous system (ANS) disorders. Based on distribution channels the market is segmented into Hospitals, Neurotherapeutic center, Clinical research organizations, Clinics. Based on Geography, the Middle East and Africa Neurotherapeutics market is analyzed under various regions namely Middle East and Africa.
Major players dominating the Middle East and Africa Neurotherapeutics Market are Abbott Laboratories, Inc., Becton, Novartis AG, Dickinson and Company, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca plc, Sanofi-Aventis, Spiegelberg, stryker, Covidien, Medtronic, GE healthcare, and Merck & Co.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Neurologic Drugs
5.1.2.1 Oral Administration
5.1.2.2 Injections
5.1.2.3 Others
5.1.3 Neurologic Devices
5.1.3.1 Electroconvulsive Therapy (ECT)
5.1.3.2 Vagus Nerve Stimulation (VNS)
5.1.3.3 Transcranial magnetic stimulation
5.1.3.4 Deep Brain Stimulator
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disorders
5.2.1 Introduction
5.2.2 Central Nervous system disorder
5.2.3 Peripheral Nervous system disorder
5.2.4 Autonomous Nervous system disorder
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Distribution Channels
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Neurotherapeutic center
5.3.4 Clinical Research organisations
5.3.5 Clinics
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Disorders
6.1.3.4 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Disorders
6.1.4.4 By Distributional Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Disorders
6.1.5.4 By Distribution channels
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Novartis AG
8.4 Dickinson and Company
8.5 Pfizer
8.6 Johnson & Johnson
8.7 Biogen
8.8 Glaxosmithkline
8.9 AstraZeneca
8.10 Sanofi Aventis
8.11 Spiegelberg
8.12 Covidien
8.13 Medtronic
8.14 GE Health Care
8.15 Merck & Co
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
